FindTrial
Sign In

Prognostic value of systemic inflammatory markers in MYCN-amplified neuroblastoma patients: a retrospective study based on medical records

Prognostic value of systemic inflammatory markers in MYCN-amplified neuroblastoma patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044445
Enrollment
Unknown
Registered
2021-03-18
Start date
2021-03-19
Completion date
Unknown
Last updated
2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroblastoma

Interventions

case series:Nil

Sponsors

West China Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 12 Years

Inclusion criteria

Inclusion criteria: (1) Complete clinical data; (2) Clear pathological diagnosis; (3) Before data collection, there were no blood transfusion, chemotherapy, infection or other related abnormalities that could affect the results of routine blood count.

Exclusion criteria

Exclusion criteria: (1) History of other malignant tumors, hematological and autoimmune diseases; (2) survival time <= 3 months; (3) acute inflammatory reaction or infectious diseases and related complications; (4) patients with missing results of hematological routine examination within one week before operation; (5) patients with neoadjuvant chemotherapy.

Design outcomes

Primary

MeasureTime frame
systemic inflammatory markers;—

Countries

China

Contacts

Public ContactLyu Yong

West China Hospital, Sichuan University

xb_scu_edu@163.com+86 18141646570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026